Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Worsening a patient's credit can prevent them from getting a job, renting an apartment, or even paying their outstanding ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Humana has refiled its lawsuit against the federal government over its Medicare Advantage ratings, with billions of dollars ...

The FDA on Tuesday rejected a skin therapy from Replimune Group, suggesting a hardened stance on drug approvals under new agency officials ...

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing ...

“Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development — ...

CASP, the protein structure prediction contest that launched DeepMind’s Alphafold to international fame and a Nobel Prize, ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

WASHINGTON — President Trump’s major domestic policy law will result in nearly 10 million more people going without health ...